Identification of Immune Checkpoint Inhibitor-Induced Diabetes.

ABSTRACT:

Importance

Immune checkpoint inhibitors (ICIs) have revolutionized cancer care; however, accompanying immune-related adverse events (irAEs) confer substantial morbidity and occasional mortality. Life-threatening irAEs may require permanent cessation of ICI, even in patients with positive tumor response. Therefore, it is imperative to comprehensively define the spectrum of irAEs to aid individualized decision-making around the initiation of ICI therapy.

Objective

To define incidence, risk factors, and clinical spectrum of an irreversible and life-threatening irAE: ICI-induced diabetes.

Design, setting, and participants

This cohort study, conducted at an academic integrated health care system examined 14 328 adult patients treated with ICIs, including 64 patients who de

SUBMITTER: Ruiz-Esteves KN 

PROVIDER: S-EPMC11362970 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature